Opexa Publication Of Tovaxin(R) Clinical Data In Journal Of Clinical Immunology

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS) and a stem cell therapy for diabetes, today announced that data from its Phase I/II dose escalation study has been recently published in the May 2009 edition of the prestigious Journal of Clinical Immunology. Encouraging data from this clinical study paved the way for the larger Phase IIb TERMS trial that was completed in late 2008.

More: continued here

Filed under: Diabetes on May 3rd, 2009